Discover why BVNKF's vaccine innovations, growth catalysts, and compelling valuation after a 52% pullback make it a strong ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US Government to add to vaccine ...

Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s ...

Yesterday the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Bavarian Nordic's mpox vaccine, ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

In a statement on Thursday, April 10, the Health Cabinet Secretary, Aden Duale, confirmed that the country has received ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This recent safety and effectiveness data regarding mpox vaccination with Jynneos is important and timely given the ongoing ...

Health Cabinet Secretary Aden Duale has called on Kenyans to remain vigilant and strictly adhere to public health measures as ...

Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its ...

The full proposals are available on the notice for the Annual General Meeting. Minutes and voting results from the Annual General Meeting will be published on the Company's website within two weeks.

The Company has been contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a freeze-dried version of JYNNEOS for stockpiling. Manufacturing under ...